secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2021-11-19T23:59:59+00:00
Accession:  0001104659-21-141614
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Voyager CFO Allison Dorval resigns; Julie Burek appointed CFO effective Nov 26, 2021
--------------------------------------------------------------------------------

- Allison Dorval resignation as CFO effective Nov 26, 2021, to pursue role at another company.
- Dorval to enter separation agreement and consulting contract through Jan 14, 2022.
- During consulting period, existing RSUs and stock options continue vesting as if employed.
- Julie Burek, VP of Finance since Aug 2020, appointed principal financial and accounting officer.
- Burek receives option for 25,000 shares effective Nov 26, 2021, and RSU for 13,500 shares effective Jan 1, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000110465921141614/0001104659-21-141614-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000110465921141614/tm2133470d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-141614

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer